Katelyn Downey

Katelyn Downey

Auto-generated profile, based on publicly available information

Katelyn Downey

Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
KDKatelyn Downey
Katelyn Downey
RZRichard Zhang
Richard Zhang
ALAlex Ortega Loayza
Alex Ortega Loayza
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis strongly associated with inflammatory bowel disease (IBD). This narrative review summarizes current knowledge on the epidemiology, clinical features, proposed mechanisms, and treatment of PG in patients with IBD. In addition to population-based, large cohort, and mechanistic studies, we reviewed 115 published case reports and case series describing patients with PG and IBD and synthesized demographic, clinical, and therapeutic trends. Most patients developed PG after an IBD diagnosis, with smaller proportions presenting simultaneously or before an IBD diagnosis. PG in IBD patients typically affects middle-aged adults and has a female predominance. Clinical features are heterogeneous, which complicates recognition and timely diagnosis. Treatment responses are also highly variable. Corticosteroids and immunosuppressants are commonly used as first-line therapies, but many patients require sequential or combined regimens. Biologics are increasingly used, reflecting efforts to target shared inflammatory pathways between PG and IBD; however, treatment approaches remain highly individualized. Mechanistic and genetic studies implicate Th17/Th1 immune dysregulation, IL-1β/IL-36 signaling, and gut-skin immune crosstalk. There is a critical need for longitudinal, controlled studies to clarify pathogenesis, predict outcomes, and guide evidence-based, standardized treatment approaches in this complex patient population.

14 October 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
CMCatherine R Marinac
Catherine R Marinac
KDKatelyn Downey
Katelyn Downey
JPJacqueline Perry
Jacqueline Perry
BFBrittany Fisher-Longden
Brittany Fisher-Longden
TRTimothy R. Rebbeck
Timothy R. Rebbeck
BEBrian L. Egleston
Brian L. Egleston

22 September 2025 in American Journal of Clinical Dermatology
Verified
Journal Article
Closed access
PDF file
SBSarah L. Becker
Sarah L. Becker
KDKatelyn Downey
Katelyn Downey
JNJustin Ng
Justin Ng
ALAlex Ortega Loayza
Alex Ortega Loayza

25 December 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
KRKatelin R. Ross
Katelin R. Ross
MSMoira Shea
Moira Shea
ELEmile Latour
Emile Latour
KDKatelyn Downey
Katelyn Downey
JGJordan Gillespie
Jordan Gillespie
ALAlex Ortega Loayza
Alex Ortega Loayza

20 July 2026 in eClinicalMedicine
Verified
Journal Article
Open access
JGJordan Gillespie
Jordan Gillespie
JRJaclyn Roland-McGowan
Jaclyn Roland-McGowan
KDKatelyn Downey
Katelyn Downey
ELEmile Latour
Emile Latour
AOAlex G. Ortega-Loayza
Alex G. Ortega-Loayza

19 June 2026 in JID Innovations
Verified
Journal Article
Open access
SBSarah L. Becker
Sarah L. Becker
RZRichard Zhang
Richard Zhang
ELEmile Latour
Emile Latour
KDKatelyn Downey
Katelyn Downey
JRJaclyn Roland-McGowan
Jaclyn Roland-McGowan
ALAlex Ortega Loayza
Alex Ortega Loayza
Pyoderma gangrenosum (PG) is a rare dermatologic disease resulting in chronic, painful ulcerations, most commonly on the lower extremity. Pruritus is a common symptom in many dermatologic conditions but has not been thoroughly evaluated in patients with PG. We sought to characterize the prevalence, severity, and impact on QOL of lesional pruritus in patients with PG. Data were obtained from the "Pyoderma Gangrenosum Study" (IRB#16753) at Oregon Health and Science University. Standardized outcome data were prospectively collected during clinical encounters from December 2019 to May 2024. Inclusion criteria were adults who presented for at least 2 clinical visits and a PARACELSUS score ≥10. We analyzed data from 136 patients with 178 ulcers. At baseline, 69% of the patients reported moderate pruritus with a mean severity of 3.3 (0-10 scale, 95% confidence interval = 2.9-3.8), which decreased with healing (from 3.7 to 2.6). QOL scores (Skindex-Mini, Wound-QoL) improved in parallel with healing. Higher pruritus severity was associated with younger age and inflammatory arthritis, whereas analgesic use and systemic therapies showed no consistent associations. In summary, our findings suggest that lesional pruritus is a common symptom among patients with PG and significantly affects their QOL. These findings support routine assessment and antipruritic interventions in the management of PG.